Comparable stake leader
Soleus Capital Master Fund, L.P.
SEC ownership of ESSA Pharma Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001633932.
Disclosed value leader
BML Investment Partners, L.P.
Comparable rows
4/10
Latest evidence
30 Sep 2025
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Soleus Capital Master Fund, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
4 of 10
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Soleus Capital Master Fund, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Sep 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001633932
- Issuer location
- Vancouver
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ESSA Pharma Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Soleus Capital Master Fun...
Disclosed value leader
BML Investment Partners, ...
Comparable rows
4/10
Latest evidence
30 Sep 2025
13D/G
3/4/5
Lead comparable stake: 9.8%
6 rows are not safely comparable across share classes.
13D/G row: Soleus Capital Master Fund, L.P.
Showing 1-8 of 10 holder rows.
Quick read
Soleus Capital Master Fund, L.P. leads the comparable SEC ownership view at 9.8%.
4 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Soleus Capital Master Fund, L.P.'s linked filing trail.
Comparable ownership
Top 4
Soleus Capital Master Fund, L.P.
9.8%
BML Investment Partners, L.P.
9.5%
MORGAN STANLEY
4%
RTW INVESTMENTS, LP
2.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. |
13D/G
|
9.8%
|
$7,415,444
4,362,026 shares
|
+$3,570,000 | 17 Jul 2025 |
| BML Investment Partners, L.P. |
13D/G
|
9.5%
|
$7,598,783
4,221,546 shares
|
+$68,981 | 24 Apr 2025 |
| MORGAN STANLEY |
13D/G
|
4%
|
$456,975
1,904,062 shares
|
$0 | 30 Sep 2025 |
| RTW INVESTMENTS, LP |
13D/G
|
2.5%
|
$2,003,404
1,113,002 shares
|
$0 | 31 Dec 2024 |
| Peter Virsik |
3/4/5
Chief Operating Officer
|
—
mixed-class rows
|
$46,889
117,776 shares
mixed-class rows
|
— | 07 Oct 2024 |
| Alessandra Cesano |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
200,000 shares
|
— | 25 Mar 2024 |
| Gary Sollis |
3/4/5
Director
|
—
class O/S missing
|
—
50,000 shares
|
— | 25 Mar 2024 |
| Philip W. Kantoff |
3/4/5
Director
|
—
class O/S missing
|
—
50,000 shares
|
— | 25 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 11 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to ESSA Pharma Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
Peter Virsik
Net 12M change
$0
Latest report
09 Oct 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Peter Virsik | Chief Operating Officer | $46,889 | Filing P/S | 07 Oct 2024 | ||
| BIOTECH GROWTH N V | 10%+ Owner | $0 | Mixed | 01 Nov 2024 | ||
| Franklin M. Berger | Director | $0 | Mixed | 09 Oct 2025 | ||
| Richard M. Glickman | Director | $0 | Mixed | 09 Oct 2025 | ||
| John Alexander Martin | Director | $0 | Mixed | 09 Oct 2025 | ||
| BVF PARTNERS L P/IL | 10%+ Owner | $0 | Mixed | 09 Oct 2025 | ||
| David Ross Parkinson | President and CEO, Director | $0 | Mixed | 09 Oct 2025 | ||
| David S. Wood | Chief Financial Officer | $0 | Mixed | 09 Oct 2025 | ||
| Scott Requadt | Director | $0 | Mixed | 09 Oct 2025 | ||
| Marella Thorell | Director | $0 | Mixed | 09 Oct 2025 | ||
| Lauren Merendino | Director | Mixed | 25 Mar 2024 | |||
| Gary Sollis | Director | Mixed | 25 Mar 2024 | |||
| Alessandra Cesano | Chief Medical Officer | Mixed | 25 Mar 2024 | |||
| Sanford S. Zweifach | Director | Mixed | 25 Mar 2024 | |||
| Philip W. Kantoff | Director | Mixed | 25 Mar 2024 |
Recent insider transactions for ESSA Pharma Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David Ross Parkinson | EPIX | Common Shares | Disposed to Issuer | -100% | -65,675 | 0 | 09 Oct 2025 | Direct | ||
| David S. Wood | EPIX | Common Shares | Disposed to Issuer | -100% | -33,343 | 0 | 09 Oct 2025 | Direct | ||
| Franklin M. Berger | EPIX | Common Shares | Disposed to Issuer | -100% | -784,404 | 0 | 09 Oct 2025 | Direct | ||
| Richard M. Glickman | EPIX | Common Shares | Disposed to Issuer | -100% | -43,240 | 0 | 09 Oct 2025 | Direct | ||
| Scott Requadt | EPIX | Common Shares | Disposed to Issuer | -100% | -30,002 | 0 | 09 Oct 2025 | Direct | ||
| John Alexander Martin | EPIX | Common Shares | Disposed to Issuer | -100% | -14,299 | 0 | 09 Oct 2025 | Direct | ||
| Marella Thorell | EPIX | Common Shares | Disposed to Issuer | -100% | -2,881 | 0 | 09 Oct 2025 | Direct | ||
| Bvf Partners L P/Il | EPIX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -11,481,685 | 0 | 09 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.